Three-Dimensional in Vitro Cell Culture Models in Drug Discovery and Drug Repositioning
1,260
Citation
185
Reference
10
Related Paper
Citation Trend
Abstract:
Drug development is a lengthy and costly process that proceeds through several stages from target identification to lead discovery and optimization, preclinical validation and clinical trials culminating in approval for clinical use. An important step in this process is high-throughput screening (HTS) of small compound libraries for lead identification. Currently, the majority of cell-based HTS is being carried out on cultured cells propagated in two-dimensions (2D) on plastic surfaces optimized for tissue culture. At the same time, compelling evidence suggests that cells cultured in these non-physiological conditions are not representative of cells residing in the complex microenvironment of a tissue. This discrepancy is thought to be a significant contributor to the high failure rate in drug discovery, where only a low percentage of drugs investigated ever make it through the gamut of testing and approval to the market. Thus, three-dimensional (3D) cell culture technologies that more closely resemble in vivo cell environments are now being pursued with intensity as they are expected to accommodate better precision in drug discovery. Here we will review common approaches to 3D culture, discuss the significance of 3D cultures in drug resistance and drug repositioning and address some of the challenges of applying 3D cell cultures to high-throughput drug discovery.Keywords:
Drug Development
High-Throughput Screening
Identification
Drug repositioning
In the absence of drugs to treat or prevent COVID-19, drug repurposing can be a valuable strategy. Despite a substantial number of clinical trials, drug repurposing did not deliver on its promise. While success was observed with some repurposed drugs (e.g., remdesivir, dexamethasone, tocilizumab, baricitinib), others failed to show clinical efficacy. One reason is the lack of clear translational processes based on adequate preclinical profiling before clinical evaluation. Combined with limitations of existing in vitro and in vivo models, there is a need for a systematic approach to urgent antiviral drug development in the context of a global pandemic. We implemented a methodology to test repurposed and experimental drugs to generate robust preclinical evidence for further clinical development. This translational drug development platform comprises in vitro, ex vivo, and in vivo models of SARS-CoV-2, along with pharmacokinetic modeling and simulation approaches to evaluate exposure levels in plasma and target organs. Here, we provide examples of identified repurposed antiviral drugs tested within our multidisciplinary collaboration to highlight lessons learned in urgent antiviral drug development during the COVID-19 pandemic. Our data confirm the importance of assessing in vitro and in vivo potency in multiple assays to boost the translatability of pre-clinical data. The value of pharmacokinetic modeling and simulations for compound prioritization is also discussed. We advocate the need for a standardized translational drug development platform for mild-to-moderate COVID-19 to generate preclinical evidence in support of clinical trials. We propose clear prerequisites for progression of drug candidates for repurposing into clinical trials. Further research is needed to gain a deeper understanding of the scope and limitations of the presented translational drug development platform.
Drug repositioning
Repurposing
Drug Development
Tocilizumab
Translational Research
Approved drug
Cite
Citations (6)
The drug development is a very time consuming and complex process. Drug development Process is Expensive. Success rate for the new drug development is very small. In recent years, decreases the new drugs development. The powerful tools are developed to support the research and development (R&D) process is essential. The Drug repurposing are helpful for research and development process. The drug re-purposing as an approach finds new therapeutic uses for current candidates or existing candidates or approved drugs, different from its original application. The main aimed of Drug repurposing is to reduce costs and research time investments in Research & Development. It is used for the diagnosis and treatment of various diseases. Repositioning is important over traditional approaches and need for effective therapies. Drug re-purposing identifies new application for already banned or existing drugs from market. In drug design, drug repurposing plays important role, because it helps to preclinical development. It reducing time efforts, expenses and failures in drug discovery process. It is also called as drug repositioning, drug redirecting, drug reprofiling.
Drug repositioning
Repurposing
Drug Development
Cite
Citations (5)
Human African trypanosomiasis (HAT) is a neglected tropical disease caused by the protozoan parasite Trypanosoma brucei . Because drugs in use against HAT are toxic and require intravenous dosing, new drugs are needed. Initiating lead discovery campaigns by using chemical scaffolds from drugs approved for other indications can speed up drug discovery for neglected diseases. We demonstrated recently that the 4-anilinoquinazolines lapatinib (GW572016, 1) and canertinib (CI-1033) kill T. brucei with low micromolar EC50 values. We now report promising activity of analogues of 1, which provided an excellent starting point for optimization of the chemotype. Our compound optimization that has led to synthesis of several potent 4-anilinoquinazolines, including NEU617, 23a, a highly potent, orally bioavailable inhibitor of trypanosome replication. At the cellular level, 23a blocks duplication of the kinetoplast and arrests cytokinesis, making it a new chemical tool for studying regulation of the trypanosome cell cycle.
Drug repositioning
Repurposing
Lead compound
Lead (geology)
Neglected Tropical Diseases
Drug Development
Cite
Citations (72)
Drug repositioning (o repurposing) has become one of the most popular and successful strategies to reduce failures typically associated with drug discovery [...]
Drug repositioning
Repurposing
Cite
Citations (40)
Drug repositioning
Repurposing
Drug Development
Approved drug
Cite
Citations (388)
Repurposing
Drug repositioning
Drug Development
Approved drug
Personalized Medicine
Cite
Citations (0)
Drug repositioning
Repurposing
Business process discovery
Cite
Citations (22)
High-Throughput Screening
Chemical genetics
Chemical library
Phenotypic screening
Cite
Citations (44)
The impact of computer-aided drug designing in the field of medicinal chemistry has created a boon in the drug discovery process. Molecular docking is an integral part of bioinformatics that deals with protein-ligand interactions, binding conformations, and affinity predictions. It has shown to be a rapid, easy, and affordable method in business and research settings alike. The advancement in the hardware and software has led to enhanced molecular dynamic simulations and thus authenticate the computational results. This has created a great impact in minimizing the cost and time involved in the drug discovery process. It has also helped in identifying the rationale for drug repurposing approaches. This chapter will give in-depth knowledge of the importance of molecular docking in drug designing and discovery, their impact on drug repurposing, and success stories of the in silico approach in drug discovery and repurposing.
Drug repositioning
Repurposing
Docking (animal)
Cite
Citations (1)
Druggability
High-Throughput Screening
Identification
Business process discovery
Drug Development
ADME
Cite
Citations (8)